Adopted Trials - Leukaemia
Acronym: CAMPATH (CAM203)
Full Title
Phase II trial to evaluate the efficacy and safety of subcutaneously administered alemtuzumab (CAMPATH, MabCampath) in patients with previously treated B-Cell chronic lymphocytic leukaemia
Treatment: Simple antibodies (indirect & direct acting)
Phase: 2
Current status: Open to recruitment
Chief Investigator: Prof Andrew Pettitt
Type of trial: Early Phase
Website:
Acronym: UKCLL201 (FCM±R)
Full Title
A randomised phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
Treatment: Chemotherapy
Phase: 2
Current status: Closed to recruitment - in follow-up
Chief Investigator: Dr Peter Hillmen
Type of trial: Early Phase
Acronym: CAMFLUD (UKCLL02)
Full Title
A phase II study of alemtuzumab (MabCampath) combined with fludarabine in patients with refractory B-Cell Chronic Lymphocytic Leukaemia
Treatment: Chemotherapy
Phase: 2
Current status: Completed and closed down
Chief Investigator: Dr Peter Hillmen
Type of trial: Early Phase
Acronym: GIMI
Full Title
A pilot study of continuous imatinib mesylate vs pulsed imatinib with or without Lenograstim (rHu-G-CSF) in CML patients who have achieved a complete cytogenetic response
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 2
Current status: Completed and closed down
Chief Investigator: Prof Tessa Holyoake
Type of trial: Early Phase
Website:
Acronym: ENACT
Full Title
A phase IA/II multi-centre dose escalation study or oral AMN107 on a continuous daily dosing schedule in adult patients with gleevec (imatinib) resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL and other hematologic malignancies
Treatment: Small molecule (indirect & direct acting) (cytotoxic/targeted)
Phase: 1/2
Current status: Completed and closed down
Chief Investigator: Dr Graeme Smith
Type of trial: Early Phase
Website:
Acronym: EPIC-Healthy
Full Title
An investigation in normal subjects with HLA-A3 and HLA-B8 as an extension of an identical study in patients with chronic myeloid leukaemia
Treatment: Small molecule (indirect & direct acting) (cytotoxic/targeted)
Phase: 1/2
Current status: Completed and closed down
Chief Investigator: Prof Richard E Clark
Type of trial: Early Phase
Website:
Acronym: EPIC
Full Title
A phase I/II trial of peptide vaccination in Chronic Myeloid Leukaemia
Treatment: Small molecule (indirect & direct acting) (cytotoxic/targeted)
Phase: 1/2
Current status: Completed and closed down
Chief Investigator: Prof Richard E Clark
Type of trial: Early Phase
Website:
Acronym: CAM-PRED (UKCLL206)
Full Title
A single arm phase II study of alemtuzumab in combination with high dose methylprednisone in CLL patients with p53 deletion
Treatment: Simple antibodies (indirect & direct acting)
Phase: 2
Current status: Closed to recruitment - in follow-up
Chief Investigator: Prof Andrew Pettitt
Type of trial: Early Phase
Acronym: UK CLL Trials Biobank
Full Title
UK CLL Trials Biobank
Treatment: Other (please specify in Notes)
Phase: N/A
Current status: Open to recruitment
Chief Investigator: Prof Andrew Pettitt
Type of trial: Early Phase
Website:
Acronym: P53
Full Title
Analysis of stored samples from the UK CLL4 trial for p53 dysfunction and karyotypic complexity
Treatment: Other (please specify in Notes)
Phase: N/A
Current status: Completed and closed down
Chief Investigator: Prof Andrew Pettitt
Type of trial: Biomarkers
Website:
Acronym: UKCLL210
Full Title
Phase II trial of lenalidomide maintenance in patients with p53-deleted or FC-refractory CLL following induction therapy with alemtuzumab plus high-dose methylprednisolone
Treatment: Chemotherapy
Phase: 2
Current status: In set-up
Chief Investigator: Prof Andrew Pettitt
Type of trial: Early Phase
Website:
Acronym: MO20927
Full Title
An open-label study to characterize the safety and response rate of MabThera
(Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia
Treatment: Chemotherapy
Phase: 2
Current status: Closed to recruitment - in follow-up
Chief Investigator: Dr Peter Hillmen
Type of trial: Biomarkers
Website:
Acronym: AdMIRE
Full Title
Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia
Treatment: Chemotherapy
Phase: 2
Current status: Open to recruitment
Chief Investigator: Prof Peter Hillmen
Type of trial: Early Phase
Website:
Acronym: Drug Sensitivity Assay (
Full Title
Development and evaluation of a novel ex-vivo drug sensitivity assay as a predictive biomarker for resistance to modern combination therapy in chronic lymphocytic leukaemia
Treatment:
Phase: N/A
Current status: In set-up
Chief Investigator: Professor Andrew Pettitt
Type of trial: Biomarkers
Website:
Acronym: CLL-210
Full Title
A randomised phase II trial of alemtuzumab, dexamethasone and lenalidomide (Cam-Dex-Rev) induction followed by lenalidomide maintenance or no further treatment in high-risk CLL
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 2
Current status: In set-up
Chief Investigator: Professor Andrew Pettit
Type of trial: Early Phase
Website:
Acronym: COMPLEMENT-1
Full Title
A phase III, open label, randomized, multicentre trial of ofatumumab added to Chlorambucil V's Chlorambucil monotherapy in previously untreated patients will CLL
Treatment: Chemotherapy
Phase: 3
Current status: Open to recruitment
Chief Investigator: Prof Peter Hillmen
Type of trial: Phase 3
Website:
Acronym: LBH589
Full Title
A Phase II study of the oral sigle agent panobinostat in patients with refratory de novo or secondary acute myelogenous leukaemia (AML)
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 2
Current status: In set-up
Chief Investigator: Professor Richard Clark
Type of trial: Early Phase
Website:
Acronym: CHOICES
Full Title
A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and IM for patients with Chronic Myeloid Leukaemia (CML) in Major Cytogenetic Response (MCyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR)
Treatment: Immunological (immunotherapy & gene therapy)
Phase: 2
Current status: In set-up
Chief Investigator: Professor Tessa Holyoake
Type of trial: Early Phase
Website:
